Verve Therapeutics’ $306 Million IPO

Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now